Skip to main content
Equibles

AGARWALEYE · Dr. Agarwal's Health Care Limited

Use AGARWALEYE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AGARWALEYE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
551.30 INR -0.35 (-0.06%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 61.88K Avg daily vol (3M) 26.42K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close551.30 INR Open550.05 INR Day547.05–571.95 INR 52W close406.15–562.05 INR Avg vol 30d25K Last earningsNov 5, 2026 DataFeb 2025–Nov 2026

Latest documents

2026
Nov 5
Earnings call
Revenue and PAT surge as expansion guidance rises

Dr. Agarwal's Health Care Limited reported H1 FY27 revenue from operations of INR 1,269 crores, up 28.7%, and PAT of INR 112 crores, up 50.1%. It targets 65 facilities, including 55 surgical centers, and INR 500 crores capex.

4 source passages
For the first half of FY27, the company reported a total income of INR 1,286 crores, up 27.6% year-on-year, while revenue from operations rose 28.7% to INR 1,269 crores. Our PAT grew by 50.1% year-on-year to INR 112 crores and PAT margin expanded by around 130 basis points to 8.7%. We are now targeting an addition of 65 new facilities during the year, which includes 55 new surgical facilities as against the earlier guidance of 60 facilities, which included 40 surgical centers. So we will be revising our capex guidance upwards from INR 400 crores to INR 500 crores. Open the document at this passage
All documents

Quarterly results

Revenue Net income Net loss
· 4.31B INR 223.40M INR '25 Q3 · 4.60B INR 325.70M INR '25 Q4 · 4.87B INR 300.50M INR '26 Q1 · 4.99B INR 296.90M INR '26 Q2 ▲23% 5.30B INR 337.40M INR '26 Q3 ▲22.6% 5.64B INR 397.10M INR '26 Q4 ▲26% 6.14B INR 452.30M INR '27 Q1 LATEST ▲31.4% 6.55B INR 547.40M INR '27 Q2

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its 52-week range
Range low 406.15 INR Now 551.30 INR · 93% Range high 562.05 INR
vs 200-day avg +17% vs 50-day avg +11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

5D 20D 120D MTD YTD
XBOM:AGARWALEYE +6.7% +14.7% +15.1% +8.5% +8.4%

Exchange listing

Market
XBOM
Ticker
AGARWALEYE
ISIN
INE943P01029
Security
Ordinary share
Trading currency
INR

Company

Website
https://www.dragarwals.co.in/
Investor relations
https://www.dragarwals.co.in/

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Recent dividends

No verified dividend payments are available for this listing yet.

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

  • Earnings call · Q2 2027 2026-11-05 Transcript
    Earnings Call for the Quarter Ended September 30, 2026
  • Earnings call · Q1 2027 2026-08-04 Transcript
    Earnings Call for the Quarter Ended June 30, 2026
  • Earnings call · Q4 2026 2026-05-21 Transcript
    Earnings Call for the Quarter Ended March 31, 2026